Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 9:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–95 of 95 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Vyvanse (lisdexamfetamine dimesylate) Clear all
Terminated Phase 3 Interventional Results available

Adjunctive SPD489 to Antipsychotic Medication in Clinically Stable Adults With Persistent Predominant Negative Symptoms of Schizophrenia

NCT01738698
View directory record Official record
Conditions
Schizophrenia
Interventions
SPD489 40mg, SPD489 100mg, SPD489 160mg, Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 65 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Irving, Texas
Source: ClinicalTrials.gov public record
Updated Jun 22, 2021 · Synced Oct 13, 2026, 9:23 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder

NCT01436162
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Antidepressant + SPD489 (Lisdexamfetamine dimesylate ), Antidepressant + Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
36
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • Costa Mesa, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2021 · Synced Oct 13, 2026, 9:23 AM EDT
Completed Phase 3 Interventional Results available

Safety and Tolerability Study of SPD489 in Preschool Children Aged 4-5 Years, Diagnosed With Attention-deficit/Hyperactivity Disorder

NCT02466386
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder (ADHD)
Interventions
SPD489
Drug
Lead sponsor
Shire
Industry
Eligibility
4 Years to 5 Years
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
50
States / cities
Dothan, Alabama • Little Rock, Arkansas • Imperial, California + 41 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2021 · Synced Oct 13, 2026, 9:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Drug Interaction Study of SPD503 and Vyvanse Administered Alone and In Combination in Normal Healthy Volunteers

NCT00919867
View directory record Official record
Conditions
Healthy
Interventions
SPD503, VYVANSE, SPD503 and VYVANSE
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 45 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 14, 2021 · Synced Oct 13, 2026, 9:23 AM EDT
Terminated Phase 3 Interventional Results available

Treatment of Traumatic Brain Injury (TBI)-Related Attention Deficits

NCT01000064
View directory record Official record
Conditions
Traumatic Brain Injury, Attention Deficit Disorder
Interventions
Vyvanse, fMRI, Placebo
Drug · Procedure
Lead sponsor
Vanderbilt University
Other
Eligibility
16 Years to 45 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 19, 2017 · Synced Oct 13, 2026, 9:23 AM EDT
Completed Phase 4 Interventional Results available

Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder

NCT01552915
View directory record Official record
Conditions
Attention-deficit/Hyperactivity Disorder
Interventions
Lisdexamfetamine dimesylate, Methylphenidate Hydrochloride, Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
13 Years to 17 Years
Enrollment
464 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
79
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • National City, California + 68 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2021 · Synced Oct 13, 2026, 9:23 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Treatments for Fathers With ADHD and Their At-Risk Children (Fathers Too)

NCT02675400
View directory record Official record
Conditions
Attention Deficit/Hyperactivity Disorder (ADHD)
Interventions
Vyvanse, Behavioral Parent Training, Methylphenidate
Drug · Behavioral
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
21 Years to 55 Years · Male only
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 12, 2018 · Synced Oct 13, 2026, 9:23 AM EDT
Completed Phase 4 Interventional Results available

Cardiovascular Study of Lisdexamfetamine in Healthy and Hypertensive Attention Deficit Hyperactivity Disorder Adults

NCT00753012
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder (ADHD)
Interventions
Lisdexamfetamine
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 60 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 24, 2012 · Synced Oct 13, 2026, 9:23 AM EDT
Completed Phase 2 Interventional Results available

Forced-dose Titration of SPD489 in Adults With Binge Eating Disorder

NCT01291173
View directory record Official record
Conditions
Binge Eating Disorder
Interventions
lisdexamfetamine dimesylate (SPD489), Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 55 Years
Enrollment
271 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
31
States / cities
Little Rock, Arkansas • Beverly Hills, California • La Jolla, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2021 · Synced Oct 13, 2026, 9:23 AM EDT
Completed Phase 2 Interventional Results available

Exploratory Study of SPD489 in Adults With Major Depressive Disorder (MDD) as Augmentation Therapy to an Antidepressant

NCT00905424
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Antidepressant + SPD489 (lisdexamfetamine dimesylate), Antidepressant + placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 55 Years
Enrollment
246 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
15
States / cities
Newport Beach, California • San Diego, California • Bradenton, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2021 · Synced Oct 13, 2026, 9:23 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Vyvanse and Glucose Intolerance in Children With Attention Deficit Hyperactivity Disorder (ADHD) and Obesity

NCT01017263
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder, Glucose Intolerance, Obesity
Interventions
Lis-dexamphetamine
Drug
Lead sponsor
Duke University
Other
Eligibility
8 Years to 17 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 20, 2014 · Synced Oct 13, 2026, 9:23 AM EDT
Completed Phase 2 Interventional Results available

Shire SCT: Lisdexamfetamine Treatment for ADHD and SCT

NCT02635035
View directory record Official record
Conditions
Attention Deficit Disorder, Attention Deficit Hyperactivity Disorder
Interventions
Lisdexamfetamine, Placebo
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 60 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 16, 2021 · Synced Oct 13, 2026, 9:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Trial to Assess How Centanafadine Interacts With Stimulants in the Body

NCT07314333
View directory record Official record
Conditions
ADHD
Interventions
Centanafadine, Methylphenidate, Lisdexamfetamine
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 13, 2026, 9:23 AM EDT
Completed Phase 4 Interventional Results available

Effect of Vyvanse on Driving in Young Adults With ADHD

NCT00801229
View directory record Official record
Conditions
Attention Deficit/Hyperactivity Disorder(ADHD)
Interventions
Vyvanse, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 24 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 10, 2014 · Synced Oct 13, 2026, 9:23 AM EDT
Completed Phase 4 Interventional Results available

The Effects of Vyvanse(TM) on Brain Hemodynamics and Reading

NCT00733356
View directory record Official record
Conditions
Attention Deficit/Hyperactivity Disorder
Interventions
Vyvanse
Drug
Lead sponsor
Kimberley Lakes
Other
Eligibility
6 Years to 12 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Feb 14, 2018 · Synced Oct 13, 2026, 9:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Vyvanse and Adderall XR Given Alone and in Combination With Prilosec OTC

NCT00746733
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Lisdexamfetamine Dimesylate, Adderall XR (mixed salts amphetamine)
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 45 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 14, 2021 · Synced Oct 13, 2026, 9:23 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Attention & Memory Impairments in Menopausal Women

NCT01324024
View directory record Official record
Conditions
Symptomatic Menopause, Cognitive Impairments
Interventions
Lisdexamfetamine, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
45 Years to 60 Years · Female only
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 28, 2017 · Synced Oct 13, 2026, 9:23 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

E2 and LDX for the Treatment of Cognitive Complaints After Oophorectomy

NCT01986764
View directory record Official record
Conditions
Planned RRSO
Interventions
Lisdexamfetamine, Estradiol, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
30 Years to 48 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 24, 2017 · Synced Oct 13, 2026, 9:23 AM EDT
Completed Phase 4 Interventional Results available

Sequencing Treatments for Mothers With ADHD and Their At - Risk Children

NCT01816074
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Vyvanse (lisdexamphetamine), Behavior Parent Training
Drug · Behavioral
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
21 Years to 50 Years · Female only
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 9, 2018 · Synced Oct 13, 2026, 9:23 AM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Lisdexamfetamine in Binge Eating Disorder (BED): fMRI Effects

NCT02659488
View directory record Official record
Conditions
Binge Eating Disorder
Interventions
Lisdexamfetamine
Drug
Lead sponsor
Lindner Center of HOPE
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Mason, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 20, 2016 · Synced Oct 13, 2026, 9:23 AM EDT
Terminated Phase 3 Interventional Results available

Long-term Safety of SPD489 When Added to Stable Doses of Antipsychotic Medications in Clinically Stable Adults With Negative Symptoms of Schizophrenia

NCT01760993
View directory record Official record
Conditions
Schizophrenia
Interventions
SPD489
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 65 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
2
States / cities
Oklahoma City, Oklahoma • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 22, 2021 · Synced Oct 13, 2026, 9:23 AM EDT
Completed Phase 3 Interventional Results available

Comparison of Lisdexamfetamine Dimesylate With Atomoxetine HCl in Attention-Deficit/Hyperactivity Disorder (ADHD) Subjects With an Inadequate Response to Methylphenidate

NCT01106430
View directory record Official record
Conditions
Attention-Deficit/Hyperactivity Disorder
Interventions
Lisdexamfetamine Dimesylate, Atomoxetine Hydrochloride
Drug
Lead sponsor
Shire
Industry
Eligibility
6 Years to 17 Years
Enrollment
267 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
34
States / cities
Dothan, Alabama • Little Rock, Arkansas • Colton, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2021 · Synced Oct 13, 2026, 9:23 AM EDT
Completed Phase 3 Interventional Results available

Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder

NCT02009163
View directory record Official record
Conditions
Binge Eating Disorder
Interventions
Lisdexamfetamine dimesylate, Placebo
Drug · Other
Lead sponsor
Shire
Industry
Eligibility
18 Years to 55 Years
Enrollment
418 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
39
States / cities
Fort Myers, Florida • Lauderhill, Florida • Leesburg, Florida + 35 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2021 · Synced Oct 13, 2026, 9:23 AM EDT